Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Early Phase 1
3(100.0%)
3Total
Early Phase 1(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT05111509Early Phase 1Active Not Recruiting

A First-in-human Clinical Trial to Evaluate an Alpha-radiation Imaging Agent

Role: lead

NCT03335670Early Phase 1Active Not Recruiting

Gallium 68 Pentixafor in Patients With Neuroendocrine Tumors

Role: lead

NCT05557708Early Phase 1Not Yet Recruiting

A Safety Study of 212Pb-Pentixather Radioligand Therapy

Role: lead

All 3 trials loaded